VIM and cancer: Recently, studies in culture demonstrated three important facts: (i) that the SARS-CoV-2 receptor binding domain (RBD) surface vimentin increases the invasive potential of non-tumorigenic (MCF-10a) and cancer (MCF-7) cells; (ii) that added recombinant vimentin binds to the cell surface, enhancing the permeability of monolayers of both cell lines MCF-10a and MCF-7 to the virus; (iii) that when adding SARS-CoV-2 receptor binding domain, extracellular vimentin directly binds to it and, therefore, the permeability effects on MCF-7 are lost [37].